Edward Peres, MD
Pediatric Hematology-Oncology · Detroit, MINPI 1366480485
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,413 of the $5,055 with a category attached, or 67.5%. 5 manufacturers reported payments, led by Johnson & Johnson at 38.1% of the total. Reporting peaked in 2021 at $1,925 and has fallen 93.8% since, to $120 in 2025.
Across 11 payments — averaging $459.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Incyte Corporation$1K
- Janssen Research & Development, LLC$1K
- Novartis$254
- Takeda Pharmaceuticals U.S.A., Inc.$113
Across 62 payments — averaging $4741.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$264K
- Bristol Myers Squibb$25K
- E.r. Squibb & Sons, L.L.C.$5K
What the payments were for
- Consulting fees$3,41368%
- Travel & lodging$1,16723%
- Food & beverage$4759%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 1 | $1,925 |
| Incyte Corporation | 2 | $1,488 |
| Janssen Research & Development, LLC | 5 | $1,275 |
| Novartis | 2 | $254 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $113 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,055 in reported general payments places this provider in the 70th percentile of 84 pediatric hematology-oncology providers in Michigan.
See all pediatric hematology-oncology providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 37 | $583,780 |
| RezurockBelumosudil Mesylate | 15 | $253,718 |
| PromactaEltrombopag Olamine | 11 | $165,544 |
| PrevymisLetermovir | 12 | $81,454 |
| ZarxioFilgrastim-Sndz | 11 | $33,138 |
| Atovaquone | 20 | $13,841 |
| BexseroMeningococcal B Vaccine,4-Comp | 13 | $3,224 |
| Tacrolimus | 39 | $3,191 |
| Acyclovir | 111 | $1,859 |
| M-M-R Ii VaccineMeasles,mumps,rubella Vacc/Pf | 14 | $1,620 |
| HavrixHepatitis A Virus Vaccine/Pf | 11 | $1,135 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 17 | $1,071 |
| Hydrocortisone | 21 | $590 |
| Fluconazole | 19 | $565 |
| Magnesium Sulfate | 31 | $494 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $1,488 | $583,78037 claims |
| NovartisPromacta | $254 | $165,54411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 84 pediatric hematology-oncology providers in Michigan.
Other pediatric hematology-oncology in Detroit
- Michael CallaghanDetroit$374K
- Ahmar ZaidiDetroit$119K
- Katherine ReglingDetroit$81K
- Alexander GlarosDetroit$64K
- Brian BermanDetroit$28K
- Roland ChuDetroit$12K
- Alissa MartinDetroit$6K
- Mark ShamounDetroit$3K
- Meret HenryDetroit$3K
- Gianna ValentiDetroit$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.